Casein hydrolysate
Based on 1 Customer Validation
Casein hydrolysate is an orally effective, multi-functional mixture of bioactive peptides, a hydrolysis product of casein (HY-125865), containing ACE inhibitors and immunomodulatory target regulators, among others. Casein hydrolysate releases short-chain bioactive peptides through enzymatic hydrolysis of casein, increasing cellular glutathione and catalase levels, enhancing ConA-induced IL-2 production, and exhibiting metal ion chelation, free radical scavenging, antibacterial, and mineral absorption-promoting effects. Casein hydrolysate lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE) and reducing bradykinin degradation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 65072-00-6
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
IL-2 |
Casein hydrolysate inhibits lipid peroxidation at concentrations of 0.05-0.5 mg/mL, and can chelate Fe2+, scavenging peroxyl radicals and hydroxyl radicals[1].
The IC50 value of casein hydrolysate (0-50% (v/v); 24 h) on Jurkat T cells ranges from 19.5%-66.8% (v/v), and does not affect cell membrane integrity at concentrations ≤1% (v/v)[2].
Casein hydrolysate (0.05% (v/v); 24 h) significantly increased GSH content in Jurkat cells in antioxidant experiments, but did not affect superoxide dismutase (SOD) activity[2].
Casein hydrolysate (0.05% (v/v); 24 h) neither produced genotoxicity nor protected cells from H2O2-induced DNA damage in Caco-2 cell comet assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human Jurkat T cells
-
Concentration:0%, 0.05%, 0.10%, 0.25%, 0.50%, 1.3%, 2.5%, 5.0%, 10.0%, 25.0%, 50.0% (v/v)
-
Incubation Time:
-
Result:Exerted concentration-dependent effects on the viability of Jurkat T cells after 24 hours of treatment. The IC50 values ranged from 19.5% to 66.8% (v/v) (protein-based IC50: 1%-5.1% w/v), with hydrolysates f and g showing the lowest IC50.
Hydrolysates a, c, and d did not induce 50% cell death, and no significant increase in LDH release was observed at concentrations ≤1% (v/v), indicating no impairment of cell membrane integrity.
Casein hydrolysate-derived peptide Leu-Lys-Pro-Asp-Meth (100 μg/kg; i.v.; single dose; immediately after administration) reduces blood pressure by 30 mmHg in spontaneously hypertensive rats (SHR), and its hydrolysis product Leu-Lys-Pro (30 μg/kg; intravenous injection; single dose; immediately after administration) reduces blood pressure by 50 mmHg[1].
Casein phosphopeptides (CPP) from casein hydrolysate inhibits bone resorption, stimulates bone mineralization, and promotes calcium integration into bone tissue in a decalcified bone matrix rat model[1].
Casein hydrolysate-related immunomodulatory peptide-derived IgY prevents bacterial adhesion to the intestinal epithelium and dose-dependently prevents enterotoxigenic E. coli infection in a colostrum-deficient piglet model of enterotoxigenic E. coli infection[1].
Casein hydrolysate stimulates the production of superoxide anions by leukocytes and enhances non-specific immune defense in an Atlantic salmon (Salmo salar) immunostimulation model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Spontaneously Hypertensive Rats (SHR) hypertension model & Normotensive rats normal blood pressure model[1]
-
Dosage:Ile-Pro-Pro/Val-Pro-Pro peptides: ≤5 mg/kg; 10 mg/kg for normotensive rats
-
Administration:Single oral administration
-
Result:At doses up to 5 mg/kg significantly decreased systolic blood pressure in SHR 6 to 8 hours post-administration.
A dose of 10 mg/kg showed no effect on systolic blood pressure in normotensive rats, indicating dose-dependent and model-specific antihypertensive activity.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 65072-00-6
-
Appearance Solid
-
Color Off-white to light yellow
-
SMILES
[Casein hydrolysate]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Casein hydrolysate Related Classifications
HY-126404 Related Classifications
Powered by Bioz